MoonLake Financials - Benzinga

MoonLake Immunotherapeutics

MLTXNASDAQ

Trade with Public

Trade with Public

$11.70

0.252.18%

近くで: Sep 30, 5:00 PM EST

$11.82

0.121.03%

時間外: 7:34 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

MoonLake Financials

MoonLake (MLTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate

MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 3.45 percent increase over losses of $(0.87) per share from the same

Benzinga Newsdesk

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

Avi Kapoor

PRO
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate

MoonLake (NASDAQ:MLTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.88) by 25.14 percent. This is a 96.43 percent decrease over losses of $(0.56) per share from the

Benzinga Newsdesk

Nasdaq Jumps 150 Points; US Pending Home Sales Rise

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.

Avi Kapoor

PRO
MoonLake Q2 2025 EPS $(0.87) Misses $(0.72) Estimate

Ended the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously

Benzinga Newsdesk

PRO
MoonLake Q1 EPS $(0.63) Beats $(0.74) Estimate

MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 14.86 percent. This is a 186.36 percent decrease over losses of $(0.22) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved